Angela Lamb, MD, is the director of the Westside Mount Sinai Dermatology Faculty Practice and an associate professor of Dermatology.

The Medical Sisterhood: Balance and Boundaries in the Holiday Season, With Angela Lamb, MD

, host Mona Shahriari, MD, associate clinical professor of dermatology at Yale University, welcomes Angela Lamb, MD, associate professor of dermatology and vice chair of clinical operations and strategy at the Icahn School of Medicine at Mount Sinai. Together, they examine the realities of balancing clinical responsibilities with family life during one of the busiest—and often most emotionally taxing—times of the year.

Lamb begins by outlining her professional roles and the intentionality required to maintain a meaningful life beyond medicine. As a leader overseeing operations across a large dermatology department and as a mother of three children spanning preschool to late adolescence, she frames balance not as perfection but as continuous recalibration. She emphasizes that physicians often discuss science, therapeutics, and disease, yet true professional fulfillment is inseparable from personal well-being.

A major theme of the conversation is the importance of partnership—both at home and professionally. Lamb describes “divide and conquer” as essential, crediting her spouse’s support as a foundation for managing demanding clinical schedules and a dynamic household. She stresses that partner selection is one of the most consequential decisions physicians make, noting that qualities such as selflessness, compassion, and forgiveness enable sustainable long-term collaboration. Shahriari echoes this sentiment, reflecting on similar advice from her mentor and on how parenting reshaped her understanding of empathy and boundaries.

The episode also explores the concept of the “mental load”—the invisible cognitive labor behind daily tasks such as arranging childcare, planning holiday events, and managing household logistics. Lamb candidly describes the necessity of her “paid village,” a network of long-standing helpers who bridge the gap between work and home. She encourages women physicians to release guilt associated with outsourcing and instead evaluate what truly requires their personal attention. Tasks that do not impact long-term values, she notes, can often be delegated for the sake of emotional and logistical bandwidth.

Both physicians discuss the structural changes needed to better support physician parents. Lamb acknowledges the limitations of clinical schedules surrounding holidays and high-demand weeks. To preserve her well-being, she now takes the full week of Thanksgiving and the final two weeks of December off—an intentional shift that has improved her mental health, patient interactions, and personal fulfillment. Shahriari adds that small, purposeful adjustments, such as taking a post-travel “reset day” with her daughter, mitigate guilt and strengthen family connection.

Despite the seriousness of their discussion, moments of levity surface, including Lamb’s retelling of a near-disastrous road trip in an undercharged electric car—an anecdote that ultimately nudged her family to finally purchase a vehicle.

In closing, Lamb encourages physician mothers to lead with grace, self-forgiveness, and clarity. She urges listeners to ask directly for what they need, seek mentorship without fear of judgment, and avoid gatekeeping when supporting peers. Shahriari reinforces that authentic conversations and shared transparency form the backbone of the sisterhood the series celebrates.

As the episode concludes, both physicians remind listeners that balancing leadership, motherhood, and medicine is not about achieving perfection but about embracing community, intention, and compassion—especially during the holidays.

Editor’s note: This episode was summarized with the help of artificial intelligence tools.

Want to join The Medical Sisterhood community? Click here to join our LinkedIn Group!

Videos

In this episode, the topic of navigating the holiday season and balancing a thriving medical career and a fulfilling family life are highlighted.

The Medical Sisterhood, with Mona Shahriari, MD

The Medical Sisterhood, hosted by Mona Shahriari, MD, is a podcast dedicated to empowering female physicians by providing a platform for shared experiences, mentorship, and support. 

Each episode delves into the unique challenges women in medicine face, including work-life balance, leadership roles, and overcoming gender biases. Shahriari aims to inspire women to lead fulfilling professional and personal lives on their own terms through candid discussions and expert interviews. 

e as we foster a community where women can uplift and support each other in achieving their goals!

Dermatology

The HCPLive dermatology page is a resource for medical news and expert insights on skin disease. This page features expert-led coverage, articles, videos and research on the therapies and development of treatments for dermatologic conditions, and more.

News

news page, resources on the topics of disease- and specialty-specific medical news and expert insight can be found. Content includes articles, interviews, videos, podcasts, and breaking news on health care research, treatment, and drug development.

Clinical

clinical page is a resource for content on every specialty, disease, and topic available on our medical news site.

Podcasts

podcasts page features a feed of medical news and interview podcast series, including DocTalk, Lungcast, Derm Discussions, and Heart Trials.

Paul Whelton, MD, is a Show Chwan Health System Endowed Chair in Public Health at Tulane University.

Triple Combination Therapy Superior to Single in Lowering Blood Pressure, With Paul Whelton, MD

GMRx2, a novel low-dose triple combination of 

 drugs in a single pill, effectively lowered blood pressure (BP) compared to placebo and dual combinations in an open-label extension of a clinical trial.

American Heart Association’s (AHA) Scientific Sessions 2025

 in New Orleans, Louisiana, by Anthony Rodgers, MBChB, chair of clinical epidemiology at Imperial College London and professor of global health at the University of South Wales Sydney.

 sat down with Paul Whelton, MD, Show Chwan Health System Endowed Chair in Public Health at Tulane University and an investigator for the study, to discuss the world’s historical difficulties in managing hypertension. Whelton discussed the importance of optimizing blood pressure and the comparative efficacy of triple therapy compared to single.

“We published a large, randomized control meta-analysis in the Lancet recently. And what it showed is that with monotherapy, with any of the standard agents we use for blood pressure, you’re going to lower systolic blood pressure by about nine millimeters,” Whelton told 

. “That’s not enough. That is very rarely enough. Most people are going to need triple therapy, and if you could give that in a single pill, at a reasonable price, it’s a fantastic way to quickly control your blood pressure.”

After a 4-week, double-blind, placebo-controlled, randomized, multi-country phase, the open-label extension was conducted at 2 sites in Nigeria and 9 in Sri Lanka. Participants who had completed the randomized double-blind phase with no contraindications to the GMRx2-based treatment and who were willing to continue on GMRx2-based treatment until 52 weeks were eligible to participate.

A total of 53 patients were enrolled in the extension and were immediately started on GMRx2 ¼. Investigators initially conducted clinic visits after 2 and 4 weeks of treatment, and at 3 month intervals thereafter. If participants had a recent home mean systolic or diastolic blood pressure ≥130 and/or ≥80 mmHg, they were up-titrated to GMRx2 ½ and, if necessary, up to GMRx2 standard.

Patients measured their blood pressure at home based on AHA guidance; readings were encrypted and automatically sent to the trial database. Measurements were taken over 4 consecutive days before a trial visit, weekly afterwards, and thrice every morning and evening. Investigators also investigated blood pressure in the clinic at all visits. Lab tests for serum electrolytes and creatinine were performed at week 4, 8, 16, and 52.

The primary efficacy outcome was the percent of participants with home blood pressure control to <130/80 mmHg at week 52, and the primary safety outcome was the percent of participants who discontinued treatment due to an adverse event. Secondary outcomes included the percentage of patients with home blood pressure control to <130/80 mmHg and <135/85 mmHg, clinic blood pressure control to <140/90 mmHg at week 52, and serious adverse events, among others.

A total of 48 patients completed the open-label extension; of these, baseline mean home and clinic blood pressure levels were 129/79 mmHg and 131/83 mmHg, respectively. At week 4, mean home and clinic blood pressure were reduced to 121/78 mmHg and 126/79 mmHg, respectively. By week 52, mean home blood pressure was reduced to 120/78 mmHg, while mean clinic blood pressure was 122/77 mmHg.

Additionally, at week 52, the proportion of participants receiving GMRx2 ¼, GMRx2 ½, and GMRx2 standard doses were 53%, 27%, and 22%, respectively. Only 3 patients needed add-on therapy, and tolerability was good; no patients discontinued treatment due to an adverse event.

“We got control very quickly and it lasted throughout the year. There were no truly serious adverse events,” Whelton said. “In that sense, it was a nice demonstration that you can get good blood pressure control quickly with triple therapy, you can maintain it for a long period of time, and it’s a very safe approach.”

Rodgers A. Long-Term Efficacy and Safety of a Novel Low-Dose Triple Single-Pill Combination for the Treatment of Hypertension. Presented at the American Heart Association’s Scientific Sessions 2025. New Orleans, Louisiana. November 8-10, 2025.

Salam A, de Silva HA, Ojji D, et al. Long-Term Efficacy and Safety of a Novel Low-Dose Triple Single-Pill Combination for the Treatment of Hypertension. Glob Heart. 2025;20(1):102. Published 2025 Oct 31. 

Whelton discusses the successful results of an open-label extension investigating GMRx2, a novel triple combination pill for hypertension.

Cardiology

Cardiology condition center page is a comprehensive resource for clinical news and insights on cardiovascular and cardiometabolic diseases. This page consists of interviews, articles, podcasts, and videos on the research, treatment and development of therapies for heart disease and cardiovascular events, as well as associated diabetes, renal failure, and more...

Hypertension

The HCPLive hypertension page is a resource for medical news and expert insights on high blood pressure. This page features expert-led coverage, articles, videos and research on the therapies and development of treatments for hypertension, and more.

Conference

 conference coverage page features articles, videos, and expert-led live coverage from major medical meetings throughout the year.

Patricia Stewart, MD: Mississippi Asthma & Allergy Center  

Emergency Care Still Falling Short for Children With HAE, With Patricia Stewart, MD

frequently experience delayed or inconsistent emergency department care during acute swelling episodes, largely due to limited clinician familiarity with the condition and its treatments.

Investigator Patricia Stewart, MD, from the Mississippi Asthma & Allergy Clinic, presented these findings at the 

2025 American College of Allergy, Asthma, & Immunology Annual Scientific Meeting

 in Orlando, Florida, from November 6 – 10. During the meeting, 

sat down with Stewart to discuss what is currently known about how emergency departments treat young patients with HAE during acute attacks and what factors contribute to variation in care quality or timeliness.

“The takeaway message from this particular study was that these emergency department visits in children often lead to long term negative impressions of their condition, and this impacts them from a psychosocial standpoint for quite a number of years because of how things were handled in the emergency department at that young age,” Stewart said.

The negative experiences often derive from emergency department physicians not being familiar with HAE and not knowing what medications to give patients. Some emergency departments did not even have the appropriate medications stocked. The study also found that emergency department physicians completed unnecessary lab draws.

In the study, Stewart and colleagues gathered perspectives from pediatric (n = 23) and adolescent (n = 19) patients with HAE, their caregivers (n = 31), and healthcare providers (n = 109) to better understand what happens when children present to the ED during acute swelling episodes and how those early encounters shape their long-term psychosocial well-being.

The research drew on online discussions and video surveys that asked participants to reflect on their childhood ED visits, specifically before age 12 years. Investigators interviewed allergists, pediatricians, and nurse practitioners about their impressions of how children with HAE are managed during emergencies.

Across all groups, the message was consistent: care in the ED remains highly variable, often delayed, and sometimes distressing. In the survey, 53% of children aged 6 – 11 years and 33% aged 2 – 5 years feared when an attack may occur, 50% and 36%, respectively, missed school, 47% and 44% went to an ED during an HAE attack, 45% and 31% missed social activities, 43% and 21% were embarrassed from an HAE attack, 37% and 25% were unable to function from an HAE attack, and 20% and 16% were hospitalized for an HAE attack.Children frequently experienced prolonged swelling episodes due to delays in administering appropriate on-demand medications.

“One of the things that we can do to try to educate the emergency department providers is to provide our hereditary angioedema patients with an emergency action plan that they take to the emergency room with them, that alerts the provider of the condition and the type of medications that are used to treat hereditary angioedema,” Stewart said. “Likewise, this emergency action plan also can alert the provider in the emergency department about medications that aren't used to treat hereditary angioedema. That can lead to expedited care in cases of swelling.”

 also spoke with Raffi Tachdjian, MD, MPH, from UCLA Health, on the psychosocial impact of HAE in children.

 Similar to Stewart, Tachdjian emphasized the importance of addressing the psychosocial burden of HAE, which is higher than previously thought.

Relevant disclosures for Stewart include being on the Speaker's Bureau for Biocryst (Orladeyo) and CSL Behring (Andembry). She also recently been on advisory boards for CSL Behring and KalVista.

Stewart, P. Emergency Department Experiences of Young Patients with Hereditary Angioedema and Their Caregivers. Presented at ACAAI 2025 in Orlando, Florida from November 6 – 2025.

Tachdjian, R. Importance of Addressing the Psychosocial Burden of HAE Among Children, With Raffi Tachdjian, MD. HCPLive. November 18, 2025. 

https://www.hcplive.com/view/importance-addressing-psychosocial-burden-hae-among-children-with-raffi-tachdjian-md

Children with HAE often face delayed or inconsistent emergency care, with clinicians citing limited condition-specific knowledge as a key contributor.

Allergy

Allergy condition center page is a comprehensive resource for clinical news and insights on allergic and inflammatory diseases. This page consists of interviews, articles, podcasts, and videos on the research, treatment and development of therapies for food and seasonal allergies, as well as allergic asthma and related conditions.

Naim Alkhouri, MD, is Chief Academic Officer at Summit Clinical Research and the Director of the Steatotic Liver Disease Program at the Clinical Research Institute of Ohio.

WAYFIND: Exploring Combination Therapy for MASH Cirrhosis, With Naim Alkhouri, MD

While cirrhosis has traditionally been viewed as an irreversible stage of chronic liver disease, emerging data from pharmacologic trials have begun to challenge that notion. Among these, the phase 2 WAYFIND trial has drawn considerable attention for testing a novel combination approach in patients with biopsy-proven 

metabolic dysfunction-associated steatohepatitis (MASH)

 cirrhosis, with results recently presented at the 

American Association for the Study of Liver Diseases (AASLD) The Liver Meeting 2025

In the past 2 years, the MASH treatment landscape has seen the addition of the first 2 US Food and Drug Administration approved therapies in the form of resmetirom and semaglutide. However, neither agent indicated for patients with cirrhotic MASH, representing a substantial unmet need for this population.

Seeking to address this therapeutic gap, the Naim Alkhouri, MD, chief academic officer of Summit Clinical Research and director of the Steatotic Liver Program at North Shore Gastroenterology, and investigators on the WAYFIND trial assessed the efficacy and safety of semaglutide alone and in fixed-dose combination with cilofexor and firsocostat in patients with compensated cirrhosis due to MASH. The multicenter, double-blind, phase 2b study randomly assigned adults with biopsy-proven F4C due to MASH in a 3:3:3:2 ratio to receive semaglutide 2.4 mg/week + cilofexor 30 mg/firsocostat 20 mg/day, semaglutide 2.4 mg/week, cilofexor 30 mg/firsocostat 20 mg/day, or placebo for 72 weeks.

The primary endpoint was the proportion of patients with fibrosis improvement without MASH worsening at week 72 with semaglutdie+cilofexor/firsocostat versus placebo. Secondary (with prespecified testing hierarchy) and exploratory efficacy endpoints and safety were also assessed.

Of 457 patients who were randomized in the trial, 453 had ≥1 study drug dose. Their mean age was 62 years, 68.2% had type 2 diabetes, and mean platelets were 191×109/L.

Investigators noted there was no significant difference in the proportions of patients with fibrosis improvement without MASH worsening at week 72 with semaglutide+cilofexor/firsocostat versus placebo (13.7% vs 8.3%; 

= .2289). However, fibrosis improvement was observed with cilofexor/firsocostat versus placebo (20.3% vs 8.3%; 

Further analysis with PathAI analysis revealed a difference with semaglutide+cilofexor/firsocostat versus placebo (21.0% vs 6.0%; 

= .0011). Investigators noted MASH resolution was greater with semaglutide+cilofexor/firsocostat versus cilofexor/firsocostat or placebo and with semaglutide versus placebo in both pathologist and PathAI analyses.

The most frequent adverse events (AEs) occurring more often with semaglutide+cilofexor/firsocostat versus placebo were nausea (47.6% vs 22.6%), diarrhea (27.4% vs 17.9%), constipation (24.2% vs 8.3%), vomiting (21.8% vs 7.1%), and decreased appetite (15.3% vs 6.0%). Serious AEs and AEs leading to study discontinuation were similar across all groups. A single death occurred in each of the semaglutide and cilofexor/firsocostat groups.

“In my opinion, these data speak to the potential of reversing cirrhosis, [which has a] very high unmet need, and although we did not hit the primary endpoint, I think we see several secondary endpoints that improved with these treatments,” Alkhouri said.

Editors’ note: Alkhouri reports relevant disclosures with Altimmune, Madrigal Pharmaceuticals, Merck, Novo Nordisk, Rivus, Takeda, and others.

Alkhouri N, Kowdley K, Lawitz E, et al. A randomized, placebo-controlled, phase 2 study of the safety and efficacy of combination treatment with semaglutide, cilofexor and firsocostat in patients with compensated cirrhosis due to metabolic dysfunction-associated steatohepatitis (WAYFIND). Presented at the American Association for the Study of Liver Diseases (AASLD) The Liver Meeting 2025. Washington, DC. November 7-11, 2025.

Brooks A. Resmetirom (Rezdiffra) Receives Historic FDA Approval for Noncirrhotic NASH. HCPLive. March 14, 2024. Accessed November 18, 2025. 

https://www.hcplive.com/view/resmetirom-rezdiffra-receives-historic-fda-approval-for-noncirrhotic-nash

Brooks A. FDA Approves Semaglutide (Wegovy) Injection 2.4 mg for Noncirrhotic MASH. HCPLive. August 15, 2025. Accessed November 18, 2025. 

https://www.hcplive.com/view/fda-approves-semaglutide-wegovy-injection-2-4-mg-for-noncirrhotic-mash

Alkhouri explains findings from the phase 2 WAYFIND trial suggesting the potential of semaglutide and cilofexor/firsocostat for MASH cirrhosis.

Hepatology

MASH / MASLD

The HCPLive MASH & MASLD page is a comprehensive resource for clinical news and insights on metabolic dysfunction-associated steatotic liver disease and steatohepatitis. This page consists of interviews, articles, podcasts, and videos on the research, treatment and development of therapies for fatty liver disease, steatohepatitis, and more.

Ryan Livingston joined the MJH Life Sciences team in March of 2025, shortly after graduating from TCNJ with a bachelor’s degree in English. He enjoys creative writing, reading, and scuba diving. He can be reached at rlivingston@mjhlifesciences.com.

Image Credit: US Food and Drug Administration

Announced by Arrowhead Pharmaceuticals on November 18, 2025, the US Food and Drug Administration has approved plozasiran under the brand name REDEMPLO for the reduction of triglycerides in adult patients with familial chylomicronemia syndrome (FCS).

"Today's approval marks a pivotal moment for people living with familial chylomicronemia syndrome and the physicians who support them," Lindsey Sutton Bryan, co-founder and co-president of the FCS Foundation, said in a statement. "Because FCS symptoms are mostly invisible, this community historically has been often overlooked and misunderstood, making their journey to effective treatment especially difficult."

Plozasiran, a first-in-class investigational RNA interference therapeutic, is designed to reduce apoC-III production. ApoC-III is a major component of triglyceride-rich lipoproteins (TRLs) and a regulator of triglyceride metabolism, as it increases triglyceride levels in the blood by preventing breakdown of TRLs by lipoprotein lipase and the uptake of TRL remnants by hepatic receptors in the liver.

The FDA accepted plozasiran’s New Drug Application (NDA) on January 17, 2025, based on results from the PALISADE phase 3 trial. The application also included supportive evidence from the phase 2 SUMMIT program. PALISADE met its primary endpoint and all multiplicity-controlled key secondary endpoints, including statistically significant reductions in triglycerides, apoC-III, and acute pancreatitis incidence.

Investigators in the PALISADE trial included patients who had a fasting triglyceride level ≥880 mg/dL at screening refractory to standard lipid lowering therapy, as well as a diagnosis of FCS, who were willing to follow dietary counseling based on investigator judgment and local standard of care. Patients were excluded if they were using or had used any hepatocyte-targeted siRNA or antisense oligonucleotide molecules within the last 365 days, if they had diabetes mellitus newly diagnosed or active pancreatitis within 12 weeks before screening, if they had uncontrolled hypertension, or if they had New York Heart Association Class II, III, or IV heart failure, among other criteria.

A total of 75 participants were enrolled in PALISADE, and were randomly assigned to either 25 mg plozasiran, 50 mg plozasiran, or matching placebo, all of which were administered once every 3 months. The primary endpoint was the percent change from baseline in fasting triglycerides at month 10. Secondary endpoints included an average of the percent change from baseline in fasting triglycerides at months 10 and 12, as well as percent changes in apoC-III and non-HDL-C at months 10 and 12.

Ultimately, patients in the 25 mg arm saw a median change in triglycerides from baseline of 80% and an 83% decreased risk of acute pancreatitis versus placebo in the pooled plozasiran 25 mg and 50 mg group. Investigators also reported a favorable tolerability profile throughout the trial. The 25 mg dose also saw only the adverse events of abdominal pain, nasopharyngitis, nausea, and COVID-19.

"The FDA approval of REDEMPLO is a transformational milestone for Arrowhead. This is a proud moment for all those involved in the discovery and development process and represents new hope for the estimated 6500 people in the US living with genetic or clinical FCS," Christopher Anzalone, PhD, president and chief executive officer at Arrowhead Pharmaceuticals, said in a statement.

In a press release, Arrowhead Pharmaceuticals has confirmed that plozasiran will be available in the US before the end of 2025.

Anzalone V. Arrowhead Pharmaceuticals Announces FDA Approval of REDEMPLO (plozasiran) to Reduce Triglycerides in Adults with Familial Chylomicronemia Syndrome (FCS). BusinessWire. November 18, 2025. Accessed November 18, 2025. 

https://www.businesswire.com/news/home/20251112678197/en/Arrowhead-Pharmaceuticals-Announces-FDA-Approval-of-REDEMPLO-plozasiran-to-Reduce-Triglycerides-in-Adults-with-Familial-Chylomicronemia-Syndrome-FCS

Anzalone V. Arrowhead Pharmaceuticals Announces Acceptance of New Drug Application by U.S. FDA of Plozasiran for the Treatment of Familial Chylomicronemia Syndrome. Arrowhead Pharmaceuticals Newsroom. January 17, 2025. Accessed November 17, 2025. 

https://arrowheadpharma.com/news-press/arrowhead-pharmaceuticals-announces-acceptance-of-new-drug-application-by-u-s-fda-of-plozasiran-for-the-treatment-of-familial-chylomicronemia-syndrome/

Arrowhead Pharmaceuticals. Study of ARO-APOC3 (Plozasiran) in Adults With Familial Chylomicronemia Syndrome (FCS) (PALISADE). ClinicalTrials.gov Identifier: NCT05089084. Updated April 30, 2025. Accessed November 17, 2025. 

https://clinicaltrials.gov/study/NCT05089084

Articles

The FDA has approved plozasiran, branded as REDEMPLO, for reducing triglycerides in adults with familial chylomicronemia syndrome (FCS). This RNA interference therapeutic targets apoC-III, a key regulator of triglyceride metabolism. Approval was based on the PALISADE phase 3 trial, which demonstrated significant reductions in triglycerides and acute pancreatitis incidence. The trial included patients with high triglyceride levels unresponsive to standard therapy. Plozasiran showed a favorable safety profile, with minimal adverse events. Arrowhead Pharmaceuticals plans to make plozasiran available in the US by the end of 2025.

The FDA has approved RNA interference therapeutic plozasiran for the treatment of familial chylomicronemia syndrome.

Dyslipidemia

FDA News

FDA Approves Plozasiran for Adults With Familial Chylomicronemia Syndrome

Juan Badimon, PhD, is a professor of medicine and the director of the Atherothrombosis Research Unit at the Cardiovascular Institute of the Icahn School of Medicine at Mount Sinai.

Badimon explains the impact of sotagliflozin’s improvements in left ventricular mass, diastolic function, and 6-minute walk test results in patients without diabetes.

Heart Failure

The HCPLive heart failure page is a resource for medical news and expert insights on HF. This page features expert-led coverage, articles, videos and research on the therapies and development of treatments for heart disease, reduced and preserved ejection fraction, and more.

SOTA-P-CARDIA: Sotagliflozin Exhibits Antithrombotic Effects in Patients with HFpEF, With Juan Badimon, PhD

New qualitative findings reveal the underrecognized psychosocial burdens facing children with HAE and the unmet needs shaping their care.

Importance of Addressing the Psychosocial Burden of HAE Among Children, With Raffi Tachdjian, MD

Alex Hillenbrand is an assistant editor for 

. She earned her BA in English from Lafayette College in 2023 and went on to write for pop culture, entertainment, and sports media outlets before joining MJH Life Sciences in 2025. In her free time, Alex enjoys cooking, going on walks, and meeting new people. Contact her at mjhlifesciences.com.

Dual BLyS/APRIL inhibition with telitacicept led to significant 24h-UPCR reductions, lower progression-risk thresholds, and stable eGFR compared with placebo.


Nephrology

The HCPLive nephrology page is a resource for medical news and expert insights on kidney disease. This page features expert-led coverage, articles, videos and research on the therapies and development of treatments in nephrology, and more.

IgA Nephropathy

The HCPLive Berger disease page is a resource for medical news and expert insights on IgA nephropathy. This page features expert-led coverage, articles, videos and research on the therapies and development of treatments in Berger disease, and more.

Telitacicept Achieves Primary Endpoint in IgA Nephropathy Phase 3 Study

This November 18 episode explores early detection, diagnosis, and management of scarring alopecias and hair-care–related hair loss in patients of color.

Skin of Color Savvy: The Art and Science of Treating Patients of Color

Hosted by Skin of Color Society and produced by HCPLive, 

 delves into the latest research, clinical insights, and culturally intelligent care practices in dermatology with leading experts. 

Whether it’s groundbreaking research, practice-changing insights, or highlights from the SOCS community, this twice-monthly program provides dermatologists and care providers with expert perspectives on treating patients with skin of color.

Skin of Color Savvy: Hair-Care Challenges in Dermatology, With Amy McMichael, MD, and Kayla Taylor, MD

Panelists discuss how evidence from clinical studies supports the safety and effectiveness of new nonsteroidal treatments for children with AD.

Video Series

Peer Exchange

HCPLive® Peer Exchange panel discussions feature authoritative insights, opinions, and perspectives on important issues facing today's care professionals.

Roflumilast Efficacy and Safety in Pediatric AD

Linda Stein Gold, MD, is a dermatologist at Henry Ford Health. 

The experts analyze new patient and clinician survey data, revealing gaps between treatment satisfaction and practice realities.

Factoring Comorbidities into Diagnostic Workup for Psoriasis Patients 

Discussion on how patient goals, treatment experiences, and preference for oral agents shape individualized therapy plans.

Expert Perspectives on When to Discuss Psoriatic Arthritis With Patients 

Panelists discuss how low systemic absorption and simple dosing schedules improve safety, adherence, and caregiver confidence in pediatric AD care.

Systemic Absorption and Dosing in Pediatric AD

Professor of Rheumatology, Northwestern Feinberg School of Medicine

Ramsey-Goldman emphasized the importance of QoL in lupus, looking beyond disease scores.

Lupus

Rheumatology

Rheumatology condition center page is a comprehensive resource for clinical news and insights on rheumatologic disease. This page consists of interviews, articles, podcasts, and videos on the research, treatment and development of therapies for arthritis, gout, nr-AxSpA, and more.

Fatigue, Pain, Daily Function: DZP’s Patient-Centered Impact in SLE, with Rosalind Ramsey-Goldman, MD

Ramsey-Goldman discussed the potential of NAC for treating systemic lupus erythematosus.

Latest News

The Medical Sisterhood: Balance and Boundaries in the Holiday Season, With Angela Lamb, MD

Triple Combination Therapy Superior to Single in Lowering Blood Pressure, With Paul Whelton, MD

Emergency Care Still Falling Short for Children With HAE, With Patricia Stewart, MD

WAYFIND: Exploring Combination Therapy for MASH Cirrhosis, With Naim Alkhouri, MD

FDA Approves Plozasiran for Adults With Familial Chylomicronemia Syndrome